Organisation paid for research Program year 2025 Source: CMS Open Payments

CLS Research Center PLLC

Neither a doctor nor a teaching hospital

Research payments

$466,522

44 payments

Through program year 2025, CLS Research Center PLLC is reported as receiving $466,522 in research payments, across 44 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $20,850 5
2024 Research $87,428 15
2023 Research $67,631 14
2022 Research $31,000 3
2021 Research $242,303 6
2020 Research $17,310 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $252,061 8 payments
  2. Sanofi US Services Inc. $132,627 23 payments
  3. AstraZeneca Pharmaceuticals LP $27,144 3 payments
  4. GlaxoSmithKline, LLC. $23,685 6 payments
  5. Otsuka Pharmaceutical Co., Ltd. $16,005 3 payments
  6. Genentech, Inc. $15,000 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $151,980 4 payments
  2. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $100,033 3 payments
  3. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $81,986 13 payments
  4. A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies $50,641 10 payments
  5. BenralizUmab on AiRwAy DyNamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging.This is a phase IV,interventional single group,open label,uncontrolled,prospective,multicenter clinical trial.This study will be conducted in male and female participants 18 years old with established severe eosinophilic asthma as defined by Europe $24,753 1 payment
  6. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $23,685 6 payments
  7. PH III Study of Safety Efficacy of Cap Endonuclease in Pediatric Patients $15,000 1 payment
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of Vis649 in Participants With Immunoglobulin A (Iga) Nephropathy $10,005 2 payments
  9. Phase II of VIS649 for IgA Nephropathy $6,000 1 payment
  10. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 $2,391 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record